A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in addition to a favourable safety profile and high in vivo persistence of CAR30+ cells. The results of…
New CAR-T Therapy achieves positive results in a high proportion of patients with a refractory type of lymphoma
